咪喹莫特（艾拉 5%乳膏）或其他 TLR7 激动剂可用于治疗 COVID-19 吗？
Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
机构信息
Erciyes University, Immunology Department, Faculty of Medicine, Kayseri, Turkey.
Betul-Ziya Eren Genome and Stem Cell Center, Kayseri, Turkey; Erciyes University, Medical Biology Department, Faculty of Medicine, Kayseri, Turkey.
出版信息
Med Hypotheses. 2020 Nov;144:110202. doi: 10.1016/j.mehy.2020.110202. Epub 2020 Aug 18.
Abstract
Toll-like receptor 7 is critical in recognition of single strand RNA viruses, including SARS CoV-2, and generation of anti-viral immunity. Coronaviruses evolved strategies to dampen the host immunity. Herein, we discuss the potential use of TLR7 agonists in the early stages of COVID-19 treatment.
摘要
Toll 样受体 7 在识别单链 RNA 病毒（包括 SARS CoV-2）和产生抗病毒免疫方面至关重要。冠状病毒进化出了抑制宿主免疫的策略。在此，我们讨论了 TLR7 激动剂在 COVID-19 治疗早期的潜在用途。
相似文献
1
Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
Med Hypotheses. 2020 Nov;144:110202. doi: 10.1016/j.mehy.2020.110202. Epub 2020 Aug 18.
2
Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.
Front Immunol. 2020 Jun 11;11:1373. doi: 10.3389/fimmu.2020.01373. eCollection 2020.
3
Interferon and Toll-Like Receptor 7 Response in COVID-19: Implications of Topical Imiquimod for Prophylaxis and Treatment.
Dermatology. 2021;237(6):847-856. doi: 10.1159/000518471. Epub 2021 Aug 31.
4
Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.
Environ Res. 2020 Sep;188:109858. doi: 10.1016/j.envres.2020.109858. Epub 2020 Jun 23.
5
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
Expert Rev Vaccines. 2013 Jul;12(7):809-19. doi: 10.1586/14760584.2013.811208.
6
[New perspective in immunotherapy: local imiquimod treatment].
Orv Hetil. 2010 May 9;151(19):774-83. doi: 10.1556/OH.2010.28866.
7
TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation.
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02417-17. Print 2018 May.
8
COVID-19-associated pemphigus foliaceus exacerbated by toll-like receptor 7 agonist.
J Dermatol. 2024 Sep;51(9):e304-e305. doi: 10.1111/1346-8138.17215. Epub 2024 Apr 17.
9
SARS-CoV-2 infection and the antiviral innate immune response.
J Mol Cell Biol. 2020 Nov 26;12(12):963-967. doi: 10.1093/jmcb/mjaa071.
10
Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity.
ACS Appl Mater Interfaces. 2019 Jul 31;11(30):26637-26647. doi: 10.1021/acsami.9b08295. Epub 2019 Jul 22.
引用本文的文献
1
Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-CoV-2.
Vaccines (Basel). 2023 Mar 23;11(4):713. doi: 10.3390/vaccines11040713.
2
TIRAP, TRAM, and Toll-Like Receptors: The Untold Story.
Mediators Inflamm. 2023 Mar 7;2023:2899271. doi: 10.1155/2023/2899271. eCollection 2023.
3
Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies.
Front Cell Dev Biol. 2021 Oct 4;9:756315. doi: 10.3389/fcell.2021.756315. eCollection 2021.
4
Interferon and Toll-Like Receptor 7 Response in COVID-19: Implications of Topical Imiquimod for Prophylaxis and Treatment.
Dermatology. 2021;237(6):847-856. doi: 10.1159/000518471. Epub 2021 Aug 31.
5
Proteomics: A Tool to Study Platelet Function.
Int J Mol Sci. 2021 Apr 30;22(9):4776. doi: 10.3390/ijms22094776.
本文引用的文献
1
Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China.
Immunology. 2020 Jul;160(3):261-268. doi: 10.1111/imm.13223.
2
Preventing COVID-19-induced pneumonia with anticytokine therapy.
Lancet Rheumatol. 2020 May;2(5):e255-e256. doi: 10.1016/S2665-9913(20)30092-8. Epub 2020 Apr 6.
3
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.
Lancet. 2020 May 2;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9.
4
Type 1 interferons as a potential treatment against COVID-19.
Antiviral Res. 2020 Jun;178:104791. doi: 10.1016/j.antiviral.2020.104791. Epub 2020 Apr 7.
5
COVID-19: immunopathology and its implications for therapy.
Nat Rev Immunol. 2020 May;20(5):269-270. doi: 10.1038/s41577-020-0308-3.
6
Tocilizumab treatment in COVID-19: A single center experience.
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.
7
Coronavirus disease 2019 (COVID-19): a clinical update.
Front Med. 2020 Apr;14(2):126-135. doi: 10.1007/s11684-020-0767-8. Epub 2020 Apr 2.
8
Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).
J Microbiol Biotechnol. 2020 Mar 28;30(3):313-324. doi: 10.4014/jmb.2003.03011.
9
Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak.
Curr Biol. 2020 Apr 6;30(7):1346-1351.e2. doi: 10.1016/j.cub.2020.03.022. Epub 2020 Mar 19.
10
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
Zotero 插件